Q-omics provides the consensus-scored RNY4P14 profile across patient tissues and cancer cell-line models. RNY4P14 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RNY4P14 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RNY4P14 RNA expression shows 5,574 significant gene co-expression associations, with the highest sampling consensus in OV. Together, these results highlight CESC, BRCA, and OV as cancer lineages where RNY4P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY4P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY4P14 survival associations across molecular data types. RNY4P14 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY4P14 RNA expression–survival associations across cancer types. High RNY4P14 expression shows unfavorable associations in CESC, PAAD, OV and SKCM, but favorable associations in BLCA and GBM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RNY4P14 RNA expression.
This table summarizes RNY4P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNY4P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY4P14 shows higher tumor expression in BRCA and STAD. The BRCA box plot shows higher RNY4P14 RNA expression in tumor versus normal tissue (log2 FC = +0.157, t-test p = .007).
This table shows molecular features associated with RNY4P14 in patient tissues and cancer cell lines. In patient samples, RNY4P14 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
